Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 356 resultados
LastUpdate Última actualización 04/10/2026 [07:34:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
previousPage Resultados 350 a 356 de 356  

EXCREMENT ANALYSIS APPARATUS, ANALYSIS SYSTEM, SERVER APPARATUS, ANALYSIS METHOD, AND NON-TRANSITORY COMPUTER-READABLE MEDIUM

NºPublicación:  US20260224206A1 06/08/2026
Solicitante: 
PARAMOUNT BED CO LTD [JP]
PARAMOUNT BED CO., LTD.
US_20260224206_A1

Resumen de: US20260224206A1

An excrement analysis apparatus includes an inputter, a memory, a first analyzer, and a second analyzer. The inputter inputs imaging data captured by an image capture apparatus installed in such a way as to include, in a capturing range, an excretion range of excrement in a toilet bowl of a toilet. The memory temporarily holds the imaging data input by the inputter. The first analyzer analyzes first analysis target data being the imaging data input by the inputter, and outputs notification information to an observer who observes a user of the toilet. The second analyzer analyzes second analysis target data being the imaging data that is input by the inputter and temporarily held by the memory, and outputs detailed information indicating a content of excretion.

USE OF IFN-I ACTIVITY AS A BIOMARKER FOR TLR INHIBITOR TREATMENT

NºPublicación:  US20260227412A1 06/08/2026
Solicitante: 
MERCK PATENT GMBH [DE]
MERCK PATENT GMBH
US_20260227412_A1

Resumen de: US20260227412A1

The present invention provides for the use of IFN-I activity as a predictive biomarker for the treatment of patients with toll-like receptor (TLR) inhibitors and related uses and methods.

PEPTIDE BIOMARKER

NºPublicación:  EP4785023A1 05/08/2026
Solicitante: 
HOFFMANN LA ROCHE [CH]
F. Hoffmann-La Roche AG
WO_2025068363_A1

Resumen de: WO2025068363A1

The present invention relates to a splice variant of an ICA1 protein that acts as a biomarker for a TDP-43 pathology. In particular, the present invention relates to methods for identifying a splice variant of ICA1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and/or reduced TDP-43 function in a subject.

MATRIX FOR EXTRACORPOREAL REMOVAL OF MT-DNA FROM BLOOD

NºPublicación:  EP4786984A1 05/08/2026
Solicitante: 
BORNSTEIN STEFAN [DE]
TSELMIN SERGEY [DE]
RODIONOV ROMAN [DE]
JARZEBSKA NATALIA [DE]
KING S COLLEGE LONDON [GB]
Bornstein, Stefan
Tselmin, Sergey
Rodionov, Roman
Jarzebska, Natalia
King's College London
EP_4786984_A1

Resumen de: EP4786984A1

The invention relates to a matrix configured for use in an extracorporeal blood treatment device, wherein the matrix comprises a solid substrate, to which an agent is immobilized, wherein said agent specifically binds mitochondrial DNA (mtDNA) in the blood or blood plasma of a subject. The invention also relates to methods for preparing the matrix according to the present invention, wherein the oligonucleotide and/or the polypeptide is immobilized on the solid substrate of the matrix by covalent coupling, preferably by crosslinking. The invention further relates to a blood treatment device configured to remove mtDNA from the blood or blood plasma of a person in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix according to the present invention. The invention further relates to an extracorporeal blood circuit comprising a blood treatment device according to the present invention, wherein the extracorporeal blood circuit comprises means for transporting blood or blood plasma from a patient's vascular system to the blood treatment device at a defined flow rate and means for returning the treated blood or blood plasma back to the patient.

METHOD AND SYSTEM FOR IDENTIFYING BIOMARKERS OF A HEALTH CONDITION

NºPublicación:  EP4786977A1 05/08/2026
Solicitante: 
IMEC VZW [BE]
UNIV LEUVEN KATH [BE]
VIB VZW [BE]
Imec VZW
Katholieke Universiteit Leuven
VIB VZW
EP_4786977_PA

Resumen de: EP4786977A1

A method for identifying biomarkers of a health condition, comprising: providing a first neuronal circuit with neuronal cells from a first individual organism on a multi-electrode array, applying stimuli to the circuit, obtaining electrophysiological recordings, deriving cell-level and/or circuit-level features from the recordings, associating derived features with presence or absence of the health condition, comparing associated data with reference data, and determining if reference features or derived features are biomarkers for the condition.

COMBINATION OF OBEFAZIMOD AND ITS DERIVATIVES WITH A TNF ALPHA-INHIBITOR

Nº publicación: EP4785940A1 05/08/2026

Solicitante:

ABIVAX [FR]
ABIVAX

EP_4785940_PA

Resumen de: EP4785940A1

0001 The present invention relates to pharmaceutical combinations, pharmaceutical compositions, kits comprising a compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof, or a metabolite thereof, and a TNFα-inhibitor. The present invention also relates to said pharmaceutical combinations for use in the treatment of an inflammatory disease, disorder, or condition. The compound of formula (I) has the following formula:

traducir